Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Harvoni, Sovaldi under Review for Risks of Hypertension, Cerebrovascular Disorder
June 13, 2016
- MHLW to Set Up Subcommittee to Help Implement AMR Action Plan
June 13, 2016
- AMED to Establish New Scheme to Support Commercialization of Drug Seeds from Academia
June 10, 2016
- MHLW to Revise Guidelines on Use of Blood Products
June 10, 2016
- Upcoming ICH Meeting Expected to Approve New Members Including Generic Drug Organization
June 9, 2016
- Company Funding for AMED-Backed Clinical Research Also Subject to Legal Regulation: Govt
June 8, 2016
- Use of MID-NET in PMS Could Promote Comparisons of One’s Own Products with Other Treatments: FPMAJ Official
June 7, 2016
- MHLW to Place 2-Year Grace Period on Mandatory Barcode Labeling by March 2021 for Companies with “Special Circumstances”
June 6, 2016
- 141 Trials of Nucleic Acid Drugs Underway Worldwide, but 70% Being Conducted by US Companies: JPO Survey
June 6, 2016
- Cabinet OKs New Growth Strategy, Basic Economic and Fiscal Policy
June 3, 2016
- “Minor Discrepancies” between Marketing Approval and Actual Manufacturing Processes Found for about 70% of Products: MHLW
June 3, 2016
- Clinical Research Bill Didn’t Clear Diet, Now under Continued Review
June 2, 2016
- Tax Hike Delay Kills Feared Price Cuts in 2017, but Concerns Linger over Expensive Drug Debate
June 2, 2016
- MHLW Proposes Discontinuing Supply of Human Thrombin Products
June 2, 2016
- MHLW Expects Stable Supply of Kaketsuken’s Blood Products Despite Earthquake Damage: Official
June 2, 2016
- Bisphosphonate Labels to Add Osteonecrosis of External Auditory Canal in ADR List
June 1, 2016
- Boehringer’s Reversal Agent for Pradaxa Becomes 1st Drug Subject to Japan’s Compassionate Use Scheme
June 1, 2016
- MHLW Initiates Discussions on Palliative Care for CV Diseases
June 1, 2016
- MHLW Drug Review Panel Shelves ASKA’s Hepatic Encephalopathy Drug
May 31, 2016
- Lawmakers Eye Genomic Medicine Bill to Fuel Diagnostics Development
May 31, 2016
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…